| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 05/24/2006 | CN1257160C Aimoquinoline and aminopyridine derivatives and their use as adenosine A3 ligands |
| 05/24/2006 | CN1256976C Anti-cancer Chinese medicinal composition and its preparing method |
| 05/24/2006 | CN1256974C Compound formula chinaroot greenbrier granules and its preparation method |
| 05/24/2006 | CN1256973C Compound formula chinaroot greenbrier tablet and its preparation method |
| 05/24/2006 | CN1256971C Capsule of Chinese medicine for curing tumor |
| 05/24/2006 | CN1256955C Chinese medicine composition for curing cancer and its preparing method |
| 05/24/2006 | CN1256946C Novel method for preparing phthalocyanine metal complex and its application |
| 05/24/2006 | CN1256945C Suppository for treating cancer pain and its preparation method |
| 05/23/2006 | US7049460 Aromatic guanidine compound; antitumor agents; anticancer agents |
| 05/23/2006 | US7049439 Immunomodulators for inducing cytokine biosynthesis; viricides; antitumor agents |
| 05/23/2006 | US7049438 Quinazoline derivatives for treatment of tumours |
| 05/23/2006 | US7049422 Tumor necrosis related receptor, TR7 |
| 05/23/2006 | US7049413 MAGE-A3 peptides presented by HLA class II molecules |
| 05/23/2006 | US7049407 Antibody for use in the detection of preferential enzyme expression; for use as tool in treatment and detection of enzyme defects; for treatment autoimmune disease, inflammation, sepsis, diabetes, kidney defects and cancer |
| 05/23/2006 | US7049402 Tumor necrosis factor receptor-5 |
| 05/23/2006 | US7049345 Fat-binding polymers |
| 05/23/2006 | US7049338 Antiproliferative agents |
| 05/23/2006 | US7049332 Effective against mutations; such as 2,3-Dihydro-4-ethyl-1-(3-methylphenylamino)-5-phenyl-1H-imidazole-2-thione |
| 05/23/2006 | US7049326 Altering a drug's distribution, metabolism and elimination properties, especially by modifying with aralkyl ester moieties to increase rate of metabolism to inactive and nontoxic metabolites when exposure is halted; surgery, riots |
| 05/23/2006 | US7049322 Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor |
| 05/23/2006 | US7049316 Prodrugs of CC-1065 analogs |
| 05/23/2006 | US7049315 Solubilized topoisomerase poisons |
| 05/23/2006 | US7049313 Induce immunology response; anticancer agents |
| 05/23/2006 | US7049312 2H-1,4-benzothiazin-3(4H)-one derivative as anticarcinogenic and antiproliferative agent; inhibitors of serine/threonine and tyrosine kinase activity |
| 05/23/2006 | US7049311 Pyrrolbenzodiazepines |
| 05/23/2006 | US7049306 Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4. |
| 05/23/2006 | US7049127 Method of producing infectious reovirus |
| 05/23/2006 | US7049124 Hyaluronidase from the Hirudinaria manillensis isolation, purification and recombinant method of production |
| 05/23/2006 | US7049119 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 05/23/2006 | US7049117 Comprises chimeric polypeptide associated with uracil phosphoribosyl transferase (UPRTase) treating proliferative and infectious diseases; gene therapy; antiproliferative agents; suicide genes |
| 05/23/2006 | US7049059 Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression |
| 05/23/2006 | US7048954 Method for preparing an extract of ginkgo biloba leaves highly enriched in active principles |
| 05/23/2006 | US7048932 Preparation and standardization of immunomodulatory peptide-linked glucans with verifiable oral absorbability from coriolus versicolor |
| 05/23/2006 | CA2351207C Radionuclide labeling of vitamin b12 and coenzymes thereof |
| 05/23/2006 | CA2339630C Carboline derivatives as cgmp phosphodiesterase inhibitors |
| 05/23/2006 | CA2301189C Non-steroidal ligands for the estrogen receptor |
| 05/23/2006 | CA2201865C Laminin chains: diagnostic and therapeutic use |
| 05/23/2006 | CA2158454C Taxanes having furyl or thienyl substituted side-chain |
| 05/22/2006 | CA2485178A1 Lactic acid bacteria-derived bacteriocin and uses thereof for prevention or treatment of cancer |
| 05/18/2006 | WO2006053166A1 8h-imidazo[4,5-d]thiazolo[4,5-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same |
| 05/18/2006 | WO2006053162A1 Ptpase inhibitors and t-cell activators for treating cancer |
| 05/18/2006 | WO2006053121A2 Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity |
| 05/18/2006 | WO2006053120A1 IMIDAZO-FUSED THIAZOLO[4,5-b]PYRIDINE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME |
| 05/18/2006 | WO2006052976A2 Improved dosing regimen of temozolomide for treating cancer based on the patient’s mgmt level |
| 05/18/2006 | WO2006052913A1 PYRAZOLO[1,5-a]PYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES |
| 05/18/2006 | WO2006052712A1 Nanoparticulate compositions of tubulin inhibitor |
| 05/18/2006 | WO2006052568A2 Tgf-beta inhibitors |
| 05/18/2006 | WO2006052190A1 Indazole sulphonamide derivatives |
| 05/18/2006 | WO2006052189A1 Nitro indazole derivatives |
| 05/18/2006 | WO2006052128A1 Treatment of an intestinal adenoma and/or adenocarcinoma by inhibition of notch pathway activation |
| 05/18/2006 | WO2006051987A1 Novel drug for inhibiting estrogen-dependent diseases, prostaglandin d (pgd)-dependent gynecological diseases, immunological diseases, cancer and angiogenesis |
| 05/18/2006 | WO2006051984A1 Method of suppressing metastasis of cancer cells and medicinal composition to be used therefor |
| 05/18/2006 | WO2006051826A1 Nitrogenous heterocyclic compound and pharmaceutical use thereof |
| 05/18/2006 | WO2006051808A1 Hsp90 FAMILY PROTEIN INHIBITORS |
| 05/18/2006 | WO2006051805A1 MUTANT INTERFERON α PROTEINS AND USE THEREOF |
| 05/18/2006 | WO2006051732A1 Pharmaceutical preparation containing coated magnetic particles and method for production thereof, and diagnosis therapy system |
| 05/18/2006 | WO2006051410A1 Azabenzoxazoles for the treatment of cns disorders |
| 05/18/2006 | WO2006051290A2 Compounds for treating protein-kinase mediated disorders |
| 05/18/2006 | WO2006051270A1 5-heteroaryl thiazoles and their use as p13k inhibitors |
| 05/18/2006 | WO2006051198A1 Nanoparticles comprising an intracellular targeting element and preparation and use thereof |
| 05/18/2006 | WO2006051106A1 Combined use of vitamin d derivatives and anti-proliferative agents for treating bladder cancer |
| 05/18/2006 | WO2006050946A1 1,4 substituted pyrazolopyrimidines as kinase inhibitors |
| 05/18/2006 | WO2006050930A2 Conjugates with enhanced cell uptake activity |
| 05/18/2006 | WO2006050908A1 Inhibitors of 11βετα-hydroxy steroid dehydrogenase type 1 (11beta-hsd1) |
| 05/18/2006 | WO2006050800A1 4-amino-5-oxo-8-phenyl-5h-pyrido-[2,3-d]-pyrimidine derivatives as tyrosine kinase and raf kinase inhibitors for the treatment of tumours |
| 05/18/2006 | WO2006050779A1 N,n'-diphenyl urea derivatives suitable as kinase inhibitors |
| 05/18/2006 | WO2006050734A2 Potent lna oligonucleotides for the inhibition of hif-1a expression |
| 05/18/2006 | WO2006050732A2 Lna oligonucleotides and the treatment of cancer |
| 05/18/2006 | WO2006050591A2 Process for the synthesis of poly (vinyl alcohol) and/or poly (vinyl acetate) with spherical morphology and shell- and-nucleus structure and its use in vascular embolization |
| 05/18/2006 | WO2006032436A3 Use of microproteins as tryptase inhibitors |
| 05/18/2006 | WO2006021888B1 Dihydrofolate reductase inhibition by epigallocatechin gallate compounds |
| 05/18/2006 | WO2006021881A3 Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors |
| 05/18/2006 | WO2006020979A3 Factor vii conjugates for selectively treating neovascularization disorders |
| 05/18/2006 | WO2006018625A3 Peripheral benzodiazepine receptor independent superoxide generation |
| 05/18/2006 | WO2005113587A3 Gene products expressed differentially in tumors and use thereof |
| 05/18/2006 | WO2005097086A3 Use of 5,10-methylene tetrahydrofolate for the treatment of cancer |
| 05/18/2006 | WO2004074445A3 Model for studying the role of genes in tumor resistance to chemotherapy |
| 05/18/2006 | US20060107339 Transgenic cell comprising human leukocyte antigen binding peptide for use as tools diagnosis, prevention and treatment of cell proliferative disorders; genetic vaccines |
| 05/18/2006 | US20060106225 N3 alkylated benzimidazole derivatives as MEK inhibitors |
| 05/18/2006 | US20060106220 Compositions and therapeutic methods involving isoflavones and analogues thereof |
| 05/18/2006 | US20060106204 Bifunctional energy-reversible acyl-compositions |
| 05/18/2006 | US20060106202 Peripheral-type benzodiazepine receptor associated proteins, cloning, expression and methods of use |
| 05/18/2006 | US20060106196 treatment or prophylaxis of cancer using proteins or peptides that elicit T cell mediated immunity; vaccination |
| 05/18/2006 | US20060106111 Phenylnaphthalene compounds |
| 05/18/2006 | US20060106102 Napththalene derivatives which inhibit the cytokine or biological activity of microphage migration inhibitory factor (mif) |
| 05/18/2006 | US20060106090 Cytotoxic agents comprising taxanes and their therapeutic use |
| 05/18/2006 | US20060106082 N-[4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenylsulfonyl]-4-nitrooxybutanamide, used for the treatment of inflammatory, cardiovascular, gastrointestinal, respiratory and nervous system disorders, as analgesics, antipyretics and antocoagulants or for organ and tissue preservation |
| 05/18/2006 | US20060106073 Process for the preparation of epothilone derivatives, new epothilone derivatives as well as new intermediate products for the process and the methods of preparing same |
| 05/18/2006 | US20060106072 Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors |
| 05/18/2006 | US20060106067 Androgen receptor agonist; prostate cancer, hypogonadism; 4-[4-(hydroxymethyl)-1-piperidinyl]-1-naphthonitrile; 4-(4-hydroxy-2-methyl-1-pyrrolidinyl-1-benzothiophene-7-carbonitrile |
| 05/18/2006 | US20060106059 Melanocortin receptor ligands |
| 05/18/2006 | US20060106053 Therapy of adenocarcinoma of the colon and rectum |
| 05/18/2006 | US20060106052 Method of using sulfonamide substituted imidazoquinolines |
| 05/18/2006 | US20060106050 Thrombin receptor antagonists |
| 05/18/2006 | US20060106046 2-(3,4-difluorophenyl)-N-methyl-2-(1H-1,2,3-triazol-1-yl)-N-[3-(spiro[isobenzofuran-1(3H), 4'-piperidin]-1-yl)propyl]acetamide, used for preventing or treating cardiovascular, nervous, metabolic, reproductive, respiratory and/or digestive system disorders |
| 05/18/2006 | US20060106036 Phenylpyrazole compounds such as 1-(3-cyano-4-neopentyloxyphenyl)pyrazole-4-carboxylic acid and the like for preventing colon cancer and the like, and as an agent for suppressing tumorigenesis |
| 05/18/2006 | US20060106026 4-(4-methylpiperazin-1-ylmethyl)-n-[4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating anaplastic thyroid cancer |
| 05/18/2006 | US20060106021 ecteinascidins used for treating lung, colon, kidney, prostate, ovarian, breast and pancreatic cancers, leukaemia or melanoma |
| 05/18/2006 | US20060106019 Novel substituted pyrazolo[1,5 a]-1,3,5-triazine derivatives and their analogues, pharmaceutical compositions containing same, use thereof as medicine and methods for preparing same |
| 05/18/2006 | US20060106006 Including vanadocene dihalides, bis(methylcyclopentadienyl), vanadocene diazide, vanadocene dicyanide, vanadocene dioxycyanate, vanadocene dithiocyanate, vanadocene diselenocyanate, vanadocene ditriflate, vanadocene monochloro oxycyanate, vanadocene monochloro acetonitrilo tetrachloro ferrate |